Subsequent Events	9 Months Ended
Sep. 30, 2015
Notes to Financial Statements
Note 13 - Subsequent Events	On September 11, 2015, we entered into a binding letter of intent with ODIN Industries, LLC ("ODIN"). Pursuant to this letter of intent, on October 1, 2015, we and ODIN formed a new limited liability company, ODIN Applied Research Laboratories ("OARL"), to conduct a joint venture between the companies. If the transactions contemplated by the letter of intent are consummated, the joint venture will perform research and development, technology assessment and product pipeline development utilizing ODIN's patented molecular scientific process enabling reformulation of compounds, including, but not limited to the compounded pharmaceutical medications currently produced by our pharmacy and potential non-pharmaceutical applications. The closing of the transactions contemplated by the letter of intent are conditioned upon a number of conditions, including the satisfactory completion of due diligence investigations by the parties, the parties successfully raising at least $175 million of capital which would be used for operating purposes of the joint venture, completion and execution of the joint venture organizational documentation, the execution of a definitive exclusive license agreement relating to ODIN's patented molecular scientific process, and entering into employment agreements with certain ODIN personnel. In addition to the joint venture, at closing ODIN would receive approximately 10 million shares of our common stock and we would receive a 5% ownership interest in ODIN. We can terminate the letter of intent for any reason upon written notice to ODIN. We intend to close the transactions addressed in this letter of intent by March 15, 2016 and either party can terminate the agreement if funding has not occurred by that time. Each of the parties to the letter of intent is responsible for their own costs and expenses. Effective October 1, 2015, our Board of Directors ("Board") adopted the Titanium Healthcare, Inc. 2015 Equity Plan (the "Equity Plan") to enable the Board to award, retain and incentivize our officers and employees. The Board is authorized to issue up to 15,000,000 shares of the Company's common stock pursuant to the Equity Plan. Effective October 1, 2015, we entered into employment and indemnification agreements with each of our four executive officers. On October 14, 2015, we entered into another binding letter of intent with LBData, LLC ("LBData"). Pursuant to this letter of intent, on September 29, 2015, we and LBData have formed a new limited liability company, Elluminance, to conduct a joint venture between the companies. If the transactions contemplated by the letter of intent are consummated, the joint venture will capitalize on the group's expertise and applications in using sensors and supercomputing information technologies to modernize the electrical grid, improve oil and gas exploration, and also improve the transportation industry. The closing of the transactions contemplated by this letter of intent are conditioned upon a number of conditions, including the satisfactory completion of due diligence investigations by the parties, the parties successfully raising at least $10 million of capital which would be used for operating purposes of the joint venture, completion and execution of the joint venture organizational documentation, and entering into employment agreements with certain LBData personnel. We are required to fund $250,000 as soon as practical as the new joint venture's initial capital contribution, or in the event of termination, the owners of LBData will repay us $250,000 plus interest. LBData will contribute its rights to certain developed business processes, intellectual property, customer contracts and customer contacts to the joint venture. In addition to the joint venture, at closing we would issue approximately 5 million shares of our common stock to LBData. We can terminate the letter of intent for any reason upon written notice to LBData. We intend to close the transactions addressed in this letter of intent by March 15, 2016 and either party can terminate the agreement if funding has not occurred by that time. Each of the parties to the letter of intent is responsible for their own costs and expenses. In light of the changes in our business plans and the intended implementation of the two announced joint ventures, during October 2015, we have ceased fundraising under the Private Placement and intend to focus our efforts on raising the capital contemplated by the announced letters of intent.

Subsequent Events

9 Months Ended

Sep. 30, 2015

On September 11, 2015, we entered into a binding letter of intent with ODIN Industries, LLC ("ODIN"). Pursuant to this letter of intent, on October 1, 2015, we and ODIN formed a new limited liability company, ODIN Applied Research Laboratories ("OARL"), to conduct a joint venture between the companies. If the transactions contemplated by the letter of intent are consummated, the joint venture will perform research and development, technology assessment and product pipeline development utilizing ODIN's patented molecular scientific process enabling reformulation of compounds, including, but not limited to the compounded pharmaceutical medications currently produced by our pharmacy and potential non-pharmaceutical applications. The closing of the transactions contemplated by the letter of intent are conditioned upon a number of conditions, including the satisfactory completion of due diligence investigations by the parties, the parties successfully raising at least $175 million of capital which would be used for operating purposes of the joint venture, completion and execution of the joint venture organizational documentation, the execution of a definitive exclusive license agreement relating to ODIN's patented molecular scientific process, and entering into employment agreements with certain ODIN personnel. In addition to the joint venture, at closing ODIN would receive approximately 10 million shares of our common stock and we would receive a 5% ownership interest in ODIN. We can terminate the letter of intent for any reason upon written notice to ODIN. We intend to close the transactions addressed in this letter of intent by March 15, 2016 and either party can terminate the agreement if funding has not occurred by that time. Each of the parties to the letter of intent is responsible for their own costs and expenses.

Effective October 1, 2015, our Board of Directors ("Board") adopted the Titanium Healthcare, Inc. 2015 Equity Plan (the "Equity Plan") to enable the Board to award, retain and incentivize our officers and employees. The Board is authorized to issue up to 15,000,000 shares of the Company's common stock pursuant to the Equity Plan.

Effective October 1, 2015, we entered into employment and indemnification agreements with each of our four executive officers.

On October 14, 2015, we entered into another binding letter of intent with LBData, LLC ("LBData"). Pursuant to this letter of intent, on September 29, 2015, we and LBData have formed a new limited liability company, Elluminance, to conduct a joint venture between the companies. If the transactions contemplated by the letter of intent are consummated, the joint venture will capitalize on the group's expertise and applications in using sensors and supercomputing information technologies to modernize the electrical grid, improve oil and gas exploration, and also improve the transportation industry. The closing of the transactions contemplated by this letter of intent are conditioned upon a number of conditions, including the satisfactory completion of due diligence investigations by the parties, the parties successfully raising at least $10 million of capital which would be used for operating purposes of the joint venture, completion and execution of the joint venture organizational documentation, and entering into employment agreements with certain LBData personnel. We are required to fund $250,000 as soon as practical as the new joint venture's initial capital contribution, or in the event of termination, the owners of LBData will repay us $250,000 plus interest. LBData will contribute its rights to certain developed business processes, intellectual property, customer contracts and customer contacts to the joint venture. In addition to the joint venture, at closing we would issue approximately 5 million shares of our common stock to LBData. We can terminate the letter of intent for any reason upon written notice to LBData. We intend to close the transactions addressed in this letter of intent by March 15, 2016 and either party can terminate the agreement if funding has not occurred by that time. Each of the parties to the letter of intent is responsible for their own costs and expenses.

In light of the changes in our business plans and the intended implementation of the two announced joint ventures, during October 2015, we have ceased fundraising under the Private Placement and intend to focus our efforts on raising the capital contemplated by the announced letters of intent.

Titanium Healthcare, Inc. 10-Q